XYL · Investment summary · as of 3 August 2026
Priced close to what the business has demonstrated
Business type: Compounder · mature and structurally stable
The evidence needed to judge business quality is not established, so the underwriting supports no position.
At $119.16, XYL requires a -1% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 5%.
The disagreement with the market is about the growth path, and the growth margin is what the strategy ranks on.
The conditions that would settle the disagreement are dated 3 years, to 2029-08.
The value rests on an exit multiple of 27.5x, a terminal operating margin of 16% and a 8.3% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: The Q2'26 orders line reads +42% reported / +41% organic ($3,086m vs $2,174m) and the ENTIRE move is one item: Water Solutions and Services orders went $577m -> $1,449m, of which $850m is organic (+147.3%).
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The disagreement with the market is about the growth path, and the growth margin is what the strategy ranks on. |
| What do we forecast? | Revenue growth of 5% demonstrated; a terminal operating margin of 16%; an exit multiple of 27.5x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +5.2 percentage points. |
| What is it worth? | Twelve-month target $152.44, +28% from the struck price. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 27 October 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
The Q2'26 orders line reads +42% reported / +41% organic ($3,086m vs $2,174m) and the ENTIRE move is one item: Water Solutions and Services orders went $577m -> $1,449m, of which $850m is organic (+147.3%). Every other segment was flat or negative organically: Water Infrastructure -3.9%, Applied Water +9.2%, Measurement and Control +2.4%. The 10-Q names the cause: 'the securing of a significant contract in Water Solutions and Services during the three months ended June 30, 2026.' Backlog rose to $5,315m (+5.9% YoY, +15.2% vs December) and only ~40% converts to revenue in the remainder of 2026. Note the 1H organic WSS order figure (+$756m) is SMALLER than the Q2 figure (+$850m), so Q1'26 WSS organic orders were negative by roughly $94m - one lumpy award, not a trend.
Estimated probability 20%, against the 31% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
Trim or exit on valuation when the forward expected return falls below the cost of capital (8.32%) on the same reverse-DCF instrument. On approach to the $152.44 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 8% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not determined | Is the business worth owning under its declared economic type? Not established on the evidence on file. |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | The Q2'26 orders line reads +42% reported / +41% organic ($3,086m vs $2,174m) and the ENTIRE move is one item: Water Solutions and Services orders went $577m -> $1,449m, of which $850m is organic (+147.3%). |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Met | Is there a dated event that resolves the disagreement? |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +5.2 percentage points more growth than the price requires. The most important unresolved uncertainty is whether this is a business worth owning at all — the evidence for its quality is not established. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $104.86, which forces an immediate review.